LT2440231T - Agento, prijungto prie tat internalizacijos peptido, įvedimas kartu su putliųjų ląstelių degranuliacijos inhibitoriumi - Google Patents

Agento, prijungto prie tat internalizacijos peptido, įvedimas kartu su putliųjų ląstelių degranuliacijos inhibitoriumi

Info

Publication number
LT2440231T
LT2440231T LTEP10786870.5T LT10786870T LT2440231T LT 2440231 T LT2440231 T LT 2440231T LT 10786870 T LT10786870 T LT 10786870T LT 2440231 T LT2440231 T LT 2440231T
Authority
LT
Lithuania
Prior art keywords
peptido
introducing
follow
cell degranulation
agent connected
Prior art date
Application number
LTEP10786870.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Michael Tymianski
Jonathan David Garman
Hong Cui
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of LT2440231T publication Critical patent/LT2440231T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP10786870.5T 2009-06-10 2010-06-10 Agento, prijungto prie tat internalizacijos peptido, įvedimas kartu su putliųjų ląstelių degranuliacijos inhibitoriumi LT2440231T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18594309P 2009-06-10 2009-06-10
PCT/US2010/038226 WO2010144742A2 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (1)

Publication Number Publication Date
LT2440231T true LT2440231T (lt) 2020-01-10

Family

ID=43309471

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10786870.5T LT2440231T (lt) 2009-06-10 2010-06-10 Agento, prijungto prie tat internalizacijos peptido, įvedimas kartu su putliųjų ląstelių degranuliacijos inhibitoriumi

Country Status (16)

Country Link
US (4) US8933013B2 (https=)
EP (2) EP2440231B1 (https=)
JP (5) JP5886192B2 (https=)
AU (1) AU2010259986B2 (https=)
CA (2) CA3018494C (https=)
CY (1) CY1122584T1 (https=)
DK (1) DK2440231T3 (https=)
ES (1) ES2765281T3 (https=)
HR (1) HRP20192230T1 (https=)
HU (1) HUE046640T2 (https=)
LT (1) LT2440231T (https=)
PL (1) PL2440231T3 (https=)
PT (1) PT2440231T (https=)
SI (1) SI2440231T1 (https=)
SM (1) SMT202000056T1 (https=)
WO (1) WO2010144742A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
CA3018494C (en) * 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR101773431B1 (ko) 2009-09-22 2017-09-12 메디카고 인코포레이티드 식물-유래 ｖｌｐ의 제조방법
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
TW201726706A (zh) 2015-12-28 2017-08-01 出光興產股份有限公司 胜肽標記及含有其之附加標記的蛋白質
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
HUE070649T2 (hu) 2017-10-19 2025-06-28 Teijin Pharma Ltd Benzimidazol-származékok és felhasználásuk
JP2023511057A (ja) * 2020-01-09 2023-03-16 ノノ インコーポレイテッド 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
CA3203688A1 (en) 2021-01-08 2022-07-14 Jonathan David Garman Plasmin-resistant peptides for improved therapeutic index

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
WO2000034468A2 (en) 1998-12-11 2000-06-15 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
WO2003024389A2 (en) 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1601380A1 (en) * 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
CA2641421C (en) 2005-12-30 2014-07-29 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
ES2328776B1 (es) 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
CA3018494C (en) 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Also Published As

Publication number Publication date
EP3682895A1 (en) 2020-07-22
US20170043030A1 (en) 2017-02-16
CA2765171C (en) 2018-10-02
US20150126460A1 (en) 2015-05-07
US8933013B2 (en) 2015-01-13
HUE046640T2 (hu) 2020-03-30
CA3018494A1 (en) 2010-12-16
JP2018030859A (ja) 2018-03-01
SI2440231T1 (sl) 2020-08-31
PL2440231T3 (pl) 2020-05-18
JP5886192B2 (ja) 2016-03-16
SMT202000056T1 (it) 2020-03-13
AU2010259986A1 (en) 2012-01-12
JP7209364B2 (ja) 2023-01-20
EP2440231A2 (en) 2012-04-18
HRP20192230T1 (hr) 2020-03-20
US9433685B2 (en) 2016-09-06
ES2765281T3 (es) 2020-06-08
PT2440231T (pt) 2020-01-08
AU2010259986B2 (en) 2015-04-02
WO2010144742A2 (en) 2010-12-16
CA2765171A1 (en) 2010-12-16
US20120252731A1 (en) 2012-10-04
CY1122584T1 (el) 2021-01-27
JP2023017813A (ja) 2023-02-07
JP2016000735A (ja) 2016-01-07
JP6238934B2 (ja) 2017-11-29
EP2440231B1 (en) 2019-12-04
US10046060B2 (en) 2018-08-14
CA3018494C (en) 2021-12-07
EP2440231A4 (en) 2013-04-24
JP6775478B2 (ja) 2020-10-28
DK2440231T3 (da) 2020-01-13
JP2012530060A (ja) 2012-11-29
US20190038760A1 (en) 2019-02-07
JP2020125328A (ja) 2020-08-20
WO2010144742A3 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
LT2440231T (lt) Agento, prijungto prie tat internalizacijos peptido, įvedimas kartu su putliųjų ląstelių degranuliacijos inhibitoriumi
PT2606036E (pt) 2-anilinobenzimidazol-6-carboxamidas como agentes anti-inflamatórios
ME02117B (me) 2-aminobenzimidazol-5-karboksamidi kao anti-inflamatorni agensi
IL211138A0 (en) Ih-benzimidazole-5-carboxamides as anti-inflammatory agents
BRPI1014956A2 (pt) agentes antinflamatórios.
GB0816496D0 (en) Hyaluronic acid cryogel
FR2962442B1 (fr) Composition stable de 2,3,3,3-tetrafluoropropene
EP2518066A4 (en) NOVEL THROMBOCYTE AGGREGATION INHIBITOR
BRPI1009315A2 (pt) agentes anti-inflamatórios
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
PL2536370T3 (pl) Opaskowa orteza kompresyjna
EP2448654A4 (en) COMPOSITION FOR WASHING ACIDIC GAS
UY33125A (es) Diaza-espiro-[5,5]-undecanos
BRPI1011051A2 (pt) "desinfetante para as mãos"
EP2568825A4 (en) FLOWABLE LIQUID COMPOSITION
BR112012005247A2 (pt) agente antifitoviral
PL2688572T3 (pl) Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie
IL227705A (en) Domestic antifungal material, preparations containing it and uses
IL240459A0 (en) Zidkai helicase-primase, preparations containing them and their uses
PL2659889T3 (pl) Kompozycja przeciwgorączkowa/przeciwbólowa
EP2544542A4 (en) PAIN COMPOUNDS, COMPOSITIONS AND THEIR USE
BRPI1011203A2 (pt) Composição fungicida.
IT1399609B1 (it) Ifi16 extracellulare come agente terapeutico
FR2968685B1 (fr) Borne d'incendie
FR2938469B1 (fr) Timon articule